Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601003 · ClinicalTrials.gov registry record · Phase 2
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
A Phase 2 study, sponsored by Giselle Sholler.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00601003: Completed Phase 2 study, sponsored by Giselle Sholler.
NCT00601003 is a Phase 2 study that has completed, run by Giselle Sholler. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00601003, a Phase 2 study, has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
Primary Outcome
Test the safety of nifurtimox in children with relapsed or refractory neuroblastoma or medulloblastoma in combination with cyclophosphamide/topotecan
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG Nifurtimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2008-01-14 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 2 |
What the finished NCT00601003 record still lists
NCT00601003 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00601003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00601003 about?
NCT00601003 is a clinical study titled "Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma". The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
What is the current status of trial NCT00601003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2008-01-14. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT00601003?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), Nifurtimox (DRUG).
Who is sponsoring clinical trial NCT00601003?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00601003's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI